explore -WSS

explore

author：knowledge 2025-08-11 07:59:12 - browse：611

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Obesity now affects over 1 billion people worldwide, study finds

hotspot

WSS

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Covid isolation guidance eased by the CDC

RSV vaccines may be linked to small increased risk of developing GBS

In search for therapies for solid tumors, companies turn to claudin

Covid isolation guidance eased by the CDC

FogPharma raises $145 million in rare Series E round

focus

explore

explore

Drug repurposing or repositioning? The language matters

In search for therapies for solid tumors, companies turn to claudin

Cancer drug shortages should be causing more outrage

International team creates first chimeric human

Drug repurposing or repositioning? The language matters

RaDonda Vaught to speak at CommonSpirit event on patient safety

Medicare details structure of new drug price negotiation program

In search for therapies for solid tumors, companies turn to claudin

Medical leaders decry Supreme Court decision on affirmative action

Scientists unlock the key to scar

explore

FogPharma raises $145 million in rare Series E round

FDA does about

Scientists unlock the key to scar

How to address the problem of discarded donor organs

FDA does about

Flu vaccine offering decent levels of protection this winter, new data show

entertainment

knowledge

hotspot

hotspot